Regulation of β-catenin by t-DARPP in upper gastrointestinal cancer cells

Bhavatarini Vangamudi¹, Shoumin Zhu¹, Mohammed Soutto¹, Abbes Belkhiri¹ and Wael El-Rifai¹,²*

Abstract

Background: Truncated dopamine and cyclic-AMP-regulated phosphoprotein (t-DARPP) is frequently overexpressed in gastrointestinal malignancies. In this study, we examined the role of t-DARPP in regulating β-catenin.

Results: The pTopFlash construct that contains multiple TCF/LEF-binding sites was used as a measure of β-catenin/TCF transcription activity. Gastric (AGS, MKN28) and esophageal (FLO-1) adenocarcinoma cancer cell lines that lack t-DARPP expression were utilized to establish stable and transient in vitro expression models of t-DARPP. The expression of t-DARPP led to a significant induction of the pTOP reporter activity, indicative of activation of β-catenin/TCF nuclear signaling. Immunofluorescence assays supported this finding and showed accumulation and nuclear translocation of β-catenin in cells expressing t-DARPP. These cells had a significant increase in their proliferative capacity and demonstrated up-regulation of two transcription targets of β-catenin/TCF: Cyclin D1 and c-MYC. Because phosphorylated GSK-3β is inactive and loses its ability to phosphorylate β-catenin and target it towards degradation by the proteasome, we next examined the levels of phospho-GSK-3β. These results demonstrated an increase in phospho-GSK-3β and phospho-AKT. The knockdown of endogenous t-DARPP in MKN45 cancer cells demonstrated a reversal of the signaling events. To examine whether t-DARPP mediated GSK-3β phosphorylation in an AKT-dependent manner, we used a pharmacologic inhibitor of PI3K/AKT, LY294002, in cancer cells expressing t-DARPP. This treatment abolished the phosphorylation of AKT and GSK-3β leading to a reduction in β-catenin, Cyclin D1, and c-MYC protein levels.

Conclusions: Our findings demonstrate, for the first time, that t-DARPP regulates β-catenin/TCF activity, thereby implicating a novel oncogenic signaling in upper gastrointestinal cancers.

Background

Upper gastrointestinal adenocarcinomas (UGCs) are among the most prevalent causes of cancer-related deaths in the world. This category of cancers includes adenocarcinomas of the stomach, gastroesophageal junction (GEJ), and lower esophagus. While gastric carcinomas remain the world’s second leading cause of cancer-related deaths [1,2], the incidence and prevalence of adenocarcinomas of the esophagus and GEJ has dramatically increased amongst the Western population [3-6]. The biology of gastrointestinal cancer involves complex signaling mechanisms and critical molecular interactions, most of which remain uncharacterized [7-9]. Although chemotherapy is currently one of the primary options for treatment of gastric cancer, it often provides poor clinical prognosis due to the underlying resistance mechanisms [10,11]. Limited understanding of such inherent protective mechanisms enforces a need to identify novel signaling pathways that can possibly reveal novel drug targets towards the development of advanced therapeutic alternatives. Dopamine and cyclic-AMP-regulated phosphoprotein (DARPP-32), also known as PPR1R1B, is a major regulator of dopaminergic neurotransmission in the brain and is the key factor for the functioning of dopaminoceptive neurons [12]. Molecular investigation of critical target genes at 17q12 amplicon in gastric adenocarcinoma has led to the identification of DARPP-32 and t-DARPP, a truncated isoform of DARPP-32, as two novel cancer-related genes [13]. t-DARPP is frequently overexpressed in several
human adenocarcinomas such as those of the stomach, colon, esophagus, breast, and prostate [14-18]. However, the molecular signaling mechanisms governing t-DARPP’s biological functions remain fairly unexplored.

Wnt signaling is one of the most critical pathways for regulation of cell proliferation, differentiation and migration during embryonic patterning and morphogenesis [19-21]. One of the key events of canonical or Wnt/β-catenin-dependent pathways is accumulation and nuclear translocation of β-catenin, which is an integral component of adherens junctions [22-24]. Dysregulation and aberrant activation of Wnt pathways or mutations in β-catenin or adenomatous polyposis coli (APC) often results in increased β-catenin accumulation. The oncogenic potential of nuclear β-catenin in the initiation and progression of various human malignancies including carcinomas of colon and esophagus have been discussed [25-29]. Glycogen synthase kinase-3β (GSK-3β) plays an important role in determining β-catenin turnover inside the cells. In the absence of Wnt/Wingless ligand activation, β-catenin exists in the cytoplasm as a multi-protein complex with scaffold protein Axin, APC, PP2A (protein phosphatase 2A), GSK-3β, and CK1 (casein kinase I) [30-35]. When this destruction complex is intact, GSK-3β phosphorylates the amino terminal serine and threonine residues of β-catenin and targets it towards degradation by proteasomal machinery [36-38]. The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a major regulator of GSK-3β [39,40]. AKT-mediated phosphorylation and inactivation of GSK-3β leads to hypophosphorylation and stabilization of cytosolic β-catenin with subsequent accumulation and translocation into the nucleus. In the nucleus, β-catenin functions as a transcriptional co-activator of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of DNA-binding transcription factors [41-43]. This complex binds to and activates several Wnt target genes including c-MYC, Cyclin D1, MDR1, and VEGF many of which are involved in tumorigenesis [44-47]. In this study, we have reported that t-DARPP can regulate β-catenin/TCF signaling in upper gastrointestinal cancer cells.

Results
Activation of β-catenin/TCF reporter and nuclear localization of β-catenin by t-DARPP
We utilized the β-catenin reporter assays using both the pTopFlash construct, which contains six functional TCF/LEF-binding sites in the promoter of a firefly luciferase reporter gene, and the derived pPopFlash construct with mutated TCF/LEF-binding sites. The transient transfection of t-DARPP in AGS, MKN28 and FLO-1 cells that lack endogenous t-DARPP led to 3.5, 1.5, and 2.5 fold induction (p < 0.001) in the pTopFlash reporter activity relative to control pcDNA3 in AGS, MKN28, and FLO-1, respectively (Figure 1). The specificity of β-catenin/TCF was confirmed by the co-transfection of different expression vectors with mutant pPopFlash reporter. In line with these findings, the immunofluorescence studies indicated a significant increase (P < 0.001) in the percentage of cells showing accumulation and nuclear localization of β-catenin in cells transfected with t-DARPP as compared to empty vector control; AGS (86% vs 13%) and MKN28 (80% vs 26%) gastric cancer cells and FLO-1 (86% vs 20%) (Figure 2). These results augment the findings of the reporter assays and strongly suggest the possible role of t-DARPP in mediating accumulation and nuclear translocation of β-catenin and activation of β-catenin/TCF transcription complex.

 t-DARPP increases the proliferative capacity of gastric cancer cells
One of the important functions of β-catenin signaling in cancer is the promotion of cellular proliferation. Using an EDU proliferation assay and counting 500 cells from each experiment, we showed that 45-48% of AGS cells stably transfected with t-DARPP (clones #1 and #2) demonstrate nuclear EDU staining (green fluorescence) whereas only 26% of control cells showed a similar staining (p < 0.01). These results were corroborated in two independent AGS clones stably expressing t-DARPP showing a significant increase in the number of cells with nuclear EDU staining, indicative of increased cell proliferation (Figure 3).

t-DARPP expression up-regulates β-catenin and induces its targets
Accordant with our immunofluorescence results, Western blot analysis in cells stably expressing t-DARPP showed an increase in the protein levels of β-catenin in AGS and MKN28 gastric cancer cells and FLO-1 esophageal cancer cells (Figure 4). Consistent with reports that identified c-MYC and Cyclin D1 as two important targets of the β-catenin/TCF transcription complex [19,33,44,48], our results demonstrated that t-DARPP-mediated activation of β-catenin/TCF leads to up-regulation of c-MYC and Cyclin D1 in gastric and esophageal cancer cells (Figure 4). These results explain the observed increase in the proliferative capacity in t-DARPP expressing cells (Figure 3). In line with the role of active GSK-3β in regulating β-catenin degradation [19,49], our results indicated an increase in the phosphorylation levels of GSK-3β (Ser 9), indicative of the loss of GSK-3β activity (Figure 4). The PI3K/AKT signaling is one of the most fundamental pathways for cell proliferation and is frequently linked to human cancer [50-52]. Western blot analysis indicated that phosphorylation of AKT at Ser473
and Wnt/DARPP in regulating the cross-talk between PI3K/AKT together, our findings suggest the possible role of t-DARPP and its targets c-MYC and Cyclin D1 (Figure 5C). Taken together, our findings suggested the possible role of t-DARPP in regulating the cross-talk between PI3K/AKT and Wnt/β-catenin pathways in gastric carcinogenesis.

Discussion

T-DARPP has been recently identified as a splice variant of DARPP-32 [53]. Both DARPP-32 and t-DARPP genes are located at the 17q12 locus, a region frequently amplified in gastrointestinal adenocarcinomas [13,54,55].

Although DARPP-32 has been known as a major regulator of dopamine signaling in the central nervous system [56,57], the functions of DARPP-32 and t-DARPP in cancer remain largely unexplored. Our previous results indicated that t-DARPP-induced cell proliferation is possibly mediated by c-MYC and Cyclin D1 [58]. These findings suggested the possible role of t-DARPP in regulating Wnt/β-catenin signaling in cancer cells. In this study, we have identified and confirmed a novel function of t-DARPP in regulating Wnt/β-catenin signaling in upper gastrointestinal cancer cells.

Wnt signal transduction pathway is by far one of the most important pathways for regulation of cell proliferation, differentiation, migration, and survival/apoptosis. Alterations in β-catenin signaling are a common finding in several cancers [59,60]. Using the β-catenin/TCF luciferase reporter (pTopFlash) to measure the activation of β-catenin/TCF complex, t-DARPP increased the activity of this reporter in gastric and esophageal cancer cell models. The activity of Wnt/β-catenin signaling pathway depends on the accumulation and translocation of β-catenin to the nucleus, one of the important factors for the initiation of tumorigenesis in a variety of human cancers [25-27]. Accumulation and nuclear localization of β-catenin have been reported in approximately one-third of gastric tumors [25,61,62]. Immunofluorescence analysis on t-DARPP expressing cells showed remarkable accumulation of nuclear β-catenin. In the nucleus, the β-catenin/TCF transcription complex regulates the expression of several genes that are involved in human carcinogenesis such as Cyclin D1 and c-MYC [25,60-65]. The in vitro cell models expressing t-DARPP demonstrated up-regulation of Cyclin D1 and c-MYC protein levels. This finding was associated with increased proliferation in t-DARPP expressing cells as compared to...
empty vector control. Taken together, our findings provide strong evidence that t-DARPP plays a role in nuclear translocation of β-catenin and oncogenic induction of β-catenin/TCF transcriptional activity, the outcome of which is reflected in the increased proliferation capacity. In an attempt to determine the underlying signaling mechanism by which t-DARPP regulates β-catenin, we demonstrated that t-DARPP overexpression in gastric and esophageal cancer cells was associated with increased phosphorylation of GSK-3β. GSK-3β plays a critical role in Wnt/β-catenin signaling by regulating the levels of cytoplasmic β-catenin. GSK-3β is rendered inactive by phosphorylation resulting in accumulation and nuclear translocation of non-phosphorylated β-catenin [20,21]. Consistent with these studies, we detected a remarkable up-regulation in β-catenin protein levels in t-DARPP expressing cells. In line with these findings, the knockdown of exogenous and endogenous t-DARPP led to a dramatic reduction of p-GSK-3β (Ser9) and β-catenin protein levels. These results support our hypothesis that t-DARPP regulates TCF/β-catenin activity through GSK-3β phosphorylation.

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a major regulator of GSK-3β where AKT phosphorylates and inactivates GSK-3β [39,48,66,67]. In this study, we demonstrated the regulation of phospho-AKT levels by t-DARPP, and confirmed that by using a PI3K/AKT pharmacologic inhibitor (LY294002) that t-DARPP-mediated activation of β-catenin is AKT-
Figure 3 Enhanced cell proliferation of gastric cancer cells overexpressing t-DARPP. (A) AGS cells stably transfected with t-DARPP (clones #1 and #2) demonstrate an increased rate of cell proliferation (48% and 45%) as compared to pcDNA empty vector control cells (26%, p < 0.01). ClickiT® EdU Assay (Invitrogen) was utilized to measure cell proliferation in t-DARPP expressing cells. EdU (5-ethynyl-2'-deoxyuridine) is incorporated as a thymidine analog during active DNA synthesis. EdU labeling in cells is detected by the binding of azide group of Alexa Fluor 488 dye (depicted as green fluorescence) to alkyne group of EdU. Ratio of EdU positive cells to total number of cells (represented by blue nuclei stain, DAPI) is a direct index of the number of proliferating cells. (B) t-DARPP overexpression in AGS stable clones is demonstrated by Western blot from total proteins. (C) Quantification data represents results obtained from two independent t-DARPP stable clones (#1 and #2). 500 cells were counted for each experiment and the percentage of EdU positive cells for each clone was averaged from at least four independent microscopic fields. Results are representative of at least three independent experiments and shown as mean ± SD. Significance of difference was calculated using one-way ANOVA.

Figure 4 t-DARPP overexpression leads to up-regulation of β-catenin and its downstream targets. Proteins extracted from MKN28 cells stably expressing t-DARPP (pool) (A) and AGS t-DARPP stables (clones #1 and #2) (B) FLO-1 cells stably expressing t-DARPP (pool) (C) were subjected to immunoblot analysis using t-DARPP, β-catenin, c-MYC, Cyclin D1, GSK-3β, pGSK-3β (Ser9), AKT, pAKT (Ser473), and Actin antibodies. Protein loading was normalized to equal levels of β-actin. Total protein levels of β-catenin and its targets, c-MYC and Cyclin D1, were significantly higher in t-DARPP expressing cells compared to control cells. Both pGSK-3β (Ser9) and pAKT (Ser473) were higher in t-DARPP expressing cells as compared to control.
dependent. Previous reports suggested that t-DARPP provides anti-apoptotic and chemotherapeutic resistance properties to cancer cells through the activation of AKT and up-regulation of Bcl2 [17,18,68]. Taken together, the regulation of AKT by t-DARPP appears to be critical for several oncogenic functions in cancer cells.

**Conclusions**

Our findings underscore a novel oncogenic function for t-DARPP in cancer cells through regulating the β-catenin/TCF cell signaling. Further studies are necessary to explore the full impact of t-DARPP signaling mechanisms in the development and progression of gastrointestinal malignancies.

**Methods**

**Cell lines**

AGS, MKN28, MKN45, and FLO-1 cell lines were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in F-12 (HAM) medium supplemented with 5% penicillin-streptomycin (GIBCO, Grand Island, NY, USA) and 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, CA, USA) in a 37°C incubator with an atmosphere containing 5% CO₂. The pcDNA3.1 mammalian expression vector (Invitrogen) was used to generate a t-DARPP expression vector, as reported earlier [17]. AGS cell lines stably expressing t-DARPP or pcDNA3 empty vector were generated by transfection with respective expression plasmids using Lipofectamine 2000 (Invitrogen) followed by selection with 400 μg/mL of G418 antibiotic (Mediatech, Cellgro, Manassas, VA, USA) for three weeks. Stably transfected MKN28 and FLO-1 cell lines expressing t-DARPP were generated as described above, following selection with 600 μg/mL of G418 antibiotic (Mediatech, Cellgro, Manassas, VA, USA) for three weeks. Stably transfected MKN28 and FLO-1 cell lines expressing t-DARPP were generated as described above, following selection with 600 μg/mL of G418 antibiotic (Mediatech, Cellgro, Manassas, VA, USA) for three weeks. Stably transfected MKN28 and FLO-1 cell lines expressing t-DARPP were generated as described above, following selection with 600 μg/mL of G418 antibiotic (Mediatech, Cellgro, Manassas, VA, USA) for three weeks. Stably transfected MKN28 and FLO-1 cell lines expressing t-DARPP were generated as described above, following selection with 600 μg/mL of G418 antibiotic (Mediatech, Cellgro, Manassas, VA, USA) for three weeks.
Luciferase assays
TCF luciferase reporter gene constructs, pTopFlash and its mutant pFopFlash were purchased from Upstate Biotechnology (Waltham, MA, USA). Renilla luciferase (Rluc) was inserted into pcDNA3.1 vector (Invitrogen) and expressed under the control of the CMV promoter. AGS, MKN28, and FLO-1 cells (5 × 10^4) were plated in 24-well plates and transiently transfected with 500 ng of different combinations of pTopFlash, pFopFlash, pcDNA3-t-DARPP, pcDNA3 (empty vector), and 5 ng of Rluc using Fugene-6 (Roche Applied Science, Indianapolis, IN, USA) following manufacturer’s protocol. Cells were lysed 48 h post-transfection and the assays for firefly luciferase activity and Renilla luciferase activity were performed using a luminometer (Turner Designs model TD20/20). The firefly luciferase activity was normalized to Renilla luciferase activity and expressed as relative luciferase activity.

Immunofluorescence assay
AGS and MKN28 cells stably expressing t-DARPP or control vector and FLO-1 cells transiently expressing t-DARPP or control vector, were seeded onto an 8-chamber culture slide (BD Falcon, Bedford, MA, USA) (3 × 10^4 cells per chamber). After 24 h, the culture media was removed and cells were fixed in fresh 4% paraformaldehyde solution for one hour. Cells were then washed twice with cold PBS for one minute and permeabilized on ice for two minutes. After two washes with PBS, cells were incubated with 10% non-immune goat serum blocking solution (Zymed Laboratories, Carlsbad, CA, USA) for 20 min in a humidified chamber at room temperature. Next, cells were incubated with the β-catenin primary antibody (Sigma-Aldrich, St. Louis, MO, USA) prepared in PBS (1:200 dilution) for 2 h at room temperature, followed by three washes with PBS. Cells were then incubated with secondary affinipure donkey anti-rabbit IgG (Jackson Immunoresearch, West Grove, PA, USA) conjugated with fluorescein isothiocyanate (FITC) green fluorescence label prepared in PBS (1:1000 dilution) for 45 min at room temperature in a dark humidified chamber. Following three washes with PBS, cells were mounted using Vectashield/DAPI (Vector Laboratories, Burlingame, CA, USA) and visualized under a fluorescence microscope (Olympus Co., Tokyo, Japan). For analysis, all images were viewed and randomly captured at 40× magnification. For quantification, Imagej software was used. The images were transformed into 8-bit and a region of interest (ROI) was randomly selected in the nucleus and cytoplasm. The ratio of integrated density in nucleus versus cytoplasm was determined by measuring the density of the ROI in the nucleus and cytoplasm. The percentage of cells that show β-catenin nuclear staining was determined based on the value of the density ratio; a value equal to or less than 1 was considered negative, a value more than 1 was considered positive.

Western blot analysis
Protein lysates were prepared by scraping cultured cells in ice cold 1× PBS followed by centrifugation at 3500 rpm at 4°C for 10 min. Resulting protein pellets were suspended in cell lysis buffer (1% Triton X-100) containing 1% Halt protease/phosphatase inhibitor cocktail (Pierce, Rockford, IL, USA). Protein concentration was measured by a Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Proteins (10 μg/lane) were separated by SDS/polyacrylamide gel electrophoresis and then transferred onto Hybond-P polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Next, membranes were incubated with 5% non-fat dry milk blocking solution (Bio-Rad Laboratories) and target proteins were analyzed by incubating with primary antibodies specific to the proteins tested (Cell Signaling, Inc., Beverly, MA, USA).

EDU cell proliferation assay
Cell proliferation was measured using the ClickiT® EdU (5-ethyl-2’-deoxyuridine) Assay (Invitrogen) which is a specific assay that measures actively proliferating cells. EdU is incorporated as thymidine analog in the DNA of newly dividing cells and is detected by a copper catalyzed reaction with Alexa Fluor 488 dye (green fluorescence). AGS cells stably expressing t-DARPP or control vector pcDNA3 (1.5 × 10^4) were cultured in 8-well culture slides for 48 h. EdU labeling was done by incubating cells with 10 μM EdU solution prepared in pre-warmed complete culture medium at 37°C in an atmosphere containing 5% CO2 for one hour. Cells were then fixed in 3.7% paraformaldehyde solution prepared in 1 × Click iT® reaction buffer, CuSO4 solution, 1 × Click iT® reaction cocktail containing Alexa Fluor 488 dye (green fluorescence). AGS cells stably expressing t-DARPP or control vector pcDNA3 (1.5 × 10^4) were cultured in 8-well culture slides for 48 h. EdU labeling was done by incubating cells with 10 μM EdU solution prepared in pre-warmed complete culture medium at 37°C in an atmosphere containing 5% CO2 for one hour. Cells were then fixed in 3.7% paraformaldehyde solution prepared in 1 × Click iT® reaction buffer, CuSO4 solution, 1 × Click iT® reaction cocktail containing Alexa Fluor 488 dye for 30 min at room temperature in a dark humidified chamber. Before visualizing under a fluorescence microscope (Olympus Co.) at 40× magnification; cells were washed twice with 3% BSA in PBS, and then mounted using Vectashield/DAPI (Vector Laboratories). All experiments were performed in triplicate and 500 cells were counted from each experiment. The percentage of cells with nuclear EdU staining was calculated and graphed.

Knockdown by small-interfering RNA
Small-interfering oligonucleotides (siRNA) specific to targeting t-DARPP were designed using the unique
sequence, 5’UTR and exon 1, of t-DARPP. The t-DARPP siRNA and scrambled siRNA were designed and purchased from Integrated DNA Technology (Coralville, IA, USA). MKN45 cells (2 x 10^5) were cultured in a 6-well plate and transfected with different siRNA’s (described above), following the manufacturer’s protocol (Santa Cruz Biotechnology, CA, USA).

Pharmacologic inhibition of PI3K/AKT signaling
In order to confirm t-DARPP-mediated regulation of TCF/β-catenin activity via the PI3K/AKT pathway, we used LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzo pyran-4-one) to specifically inhibit phosphatidylinositol 3-Kinase activity [69]. AGS cells stably expressing t-DARPP were treated with 30 min and 2 h, as shown in Figure 5.

Statistical analysis
A two tailed student’s t-test was used to compare the statistical difference between two groups and a one-way ANOVA Newman-Keuls Multiple Comparison Test was used to compare the differences between three groups or more. The results were expressed as the mean with SD. The differences were considered statistically significant when the p value was ≤ 0.05.

Acknowledgements
This study was supported by grants from the National Institute of Health; R01CA89399 (WER), R01CA133738 (WER), Vanderbilt SPORE in Gastrointestinal Cancer (PS0 CA95103), Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or Vanderbilt University.

Author details
1Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 2Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Authors’ contributions
BV was involved in planning and performing experiments related to reporter assays, Western blot and functional assays. She summarized the data, generated the figures and contributed in writing parts of the manuscript. SZ and MS performed cell cultures and generated some of the reagents that were used. They participated in summarizing the data. AB assisted in the design of the experiments and participated in writing the Discussion section of the manuscript. WER is the principal investigator and was also involved in the design of the study, interpretation of data, troubleshooting experiments, and supervising the work relevant to this report. He participated in the writing and organization of the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 12 October 2010 Accepted: 29 March 2011
Published: 29 March 2011

References
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
4. Peta M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophago gastric junction. Recent Results Cancer Res 2000, 155:1-14.
5. Stein HJ, Feith M, Stiewert JR. Cancer of the esophagogastric junction. Surg Oncol 2000, 9:35-41.
6. Spechler SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin North Am 2002, 86:1423-1445, vii.
7. Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs 2009, 18:1351-1364.
8. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010, 10:403-414.
9. Tahara E. Genetic pathways of two types of gastric cancer. JIRC Sci Publ 2004, 327-349.
10. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 2010, 6:527-537.
11. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007, 7:1369-1378.
12. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
13. Varis A, Zaita A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, Vayrynen A, Karkkainen P, Moskaluk C, El-Rifai W, Knuttila S. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 2004, 109:548-553.
14. Beckler A, Moskaluk CA, Zaita A, Hampton GM, Powell SM, Frierson HF Jr, El-Rifai W. Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3’5’-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer 2003, 98:1457-1551.
15. Wang J, Pan YL, Liu N, Guo CC, Hong L, Fan DM. [Expression and significance of DARPP-32 in gastric carcinoma]. Zhonghua Bing Li Xue Za Zhi 2004, 33:350-353.
16. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003, 163:1979-1984.
17. Belkhiri A, Zaita A, Pidkivska N, Knuttila S, Moskaluk C, El-Rifai W. Darp-32: a novel antiapoptotic gene in upper gastrointestinal cancers. Cancer Res 2005, 65:6583-6592.
18. Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 2008, 14:4564-4571.
19. Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R. Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene 2007, 28:3546-3555.
20. Giles RH, van Erp JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1633:1-24.
21. Ikuchki A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med 2006, 38:1-10.
22. Peifer M, Sweeney D, Casey M, Wieschaus E. Wnt-1 regulates free pools of Armadillo. Development 1994, 120:369-380.
23. Pappkof J, Rubinfeld B, Schreyer B, Polakis P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol Cell Biol 1996, 16:2128-2134.
24. Wodarz A, Russe R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998, 14:59-88.
25. Motan PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
26. Damalas A, Ben-Zeév A, Simcha I, Shatuman M, Leal JF, Zhurinsky J, Geiger B, Oren M. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999, 18:3054-3063.
27. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999, 9:15-21.

28. Korinek V, Barker N, Mooi PJ, van Wichen D, de Weger R, Kindler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1878-1877.

29. Ikeno Y, Osterheld MC, Bosman FT, Fonteille C, Benhatter J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000, 114:583-580.

30. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996, 272:1023-1026.

31. Ikeda S, Kishida S, Yamamoto H, Mural H, Koyama S, Kikuchi A. Axin: a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998, 17:1371-1384.

32. Sakanaka C, Weiss JB, Williams LT. Bridging of beta-catenin and glycogen synthase kinase 3beta by axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci USA 1998, 95:3020-3023.

33. Komiyama H, Habas R. Wnt signal transduction pathways. Organogenesis 2008, 4:65-75.

34. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281:22429-22433.

35. He X, Semenov M, Tamai K, Zeng X. The Wnt signaling pathway in development and cancer. Mol Cell Biol 2006, 26:2003-2013.

36. Munemitsu S, Albert I, Rubinfeld B, Polakis P. Deletion of an amino-terminal sequence of beta-catenin in vivo and promotion of hyperphosphorylation of the adenomatous polyposis coli tumor suppressor protein. Mol Cell Biol 1996, 16:4088-4094.

37. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal organogenesis. Proc Natl Acad Sci USA 1998, 95:5130-5142.

38. Aoki H, Albert I, O’Brien JT, Rabinovitch PS, Polakis P. Constitutive transcription by the beta-catenin/Tcf complex in APC-/- colon carcinoma. Nature 1997, 385:829-833.

39. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway: a new target in human renal cell carcinoma therapy. Curr Cancer Drug Targets 2004, 4:235-256.

40. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Vogelstein B, Kinzler KW. Constitutive localization of beta-catenin by interaction with transcription factor LEF-1. Mol Cell 1996, 1:3-10.

41. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

42. Rozakis-Adcock A, Hawley RS, Thompson EW, Brown MS. Mutations in the PIK3CA gene cause constitutional activation of PI3 kinase. Science 2007, 317:1086-1089.

43. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281:22429-22433.

44. Vangamudi B, Peng DF, Cai Q, El-Rifai W, Zheng W, Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer 2009, 8:43.

45. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.

46. Vangamudi B, Peng DF, Cai Q, El-Rifai W, Zheng W, Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer 2009, 8:43.

47. Rosenbaum J, Bejsovec A. The role of Wnt signaling in cancer. Mol Cancer Ther 2008, 7:549-561.

48. Rosenbaum J, Bejsovec A. The role of Wnt signaling in cancer. Mol Cancer Ther 2008, 7:549-561.

49. Vangamudi B, Peng DF, Cai Q, El-Rifai W, Zheng W, Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer 2009, 8:43.

50. Vangamudi B, Peng DF, Cai Q, El-Rifai W, Zheng W, Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer 2009, 8:43.

51. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

52. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

53. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

54. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

55. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

56. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

57. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

58. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

59. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

60. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

61. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

62. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

63. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

64. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

65. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

66. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

67. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.

68. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. The Wnt signaling pathway in development and cancer. Mol Cell 2005, 19:449-455.